B. Yaremko

发表

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

Walter A. Korfmacher, W. R. Bishop, Jianping Chen, 1999, Cancer Chemotherapy and Pharmacology.

Inhibition of Angiogenesis and Tumor Growth by SCH221153, a Dual αvβ3 and αvβ5 Integrin Receptor Antagonist

B. Neustadt, L. Armstrong, C. Kumar, 2001 .

Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.

Patrick J. Curran, M. Williams, Ming Liu, 2010, Bioorganic & medicinal chemistry letters.

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010, Molecular Cancer Therapeutics.

Inhibition of Angiogenesis and Tumor Growth by Sch221153, a Dual ␣ V ␤ 3 and ␣ V ␤ 5 Integrin Receptor Antagonist

B. Neustadt, L. Armstrong, C. Kumar, 2022 .

Inhibition of Angiogenesis and Tumor Growth by Sch221153, Updated Version Cited Articles Citing Articles E-mail Alerts Inhibition of Angiogenesis and Tumor Growth by Sch221153, a Dual ␣ V ␤ 3 and ␣ V ␤ 5 Integrin Receptor Antagonist

B. Neustadt, L. Armstrong, C. Kumar, 2013 .

Targeting Integrins αvβ3 and αvβ5 for Bloking Tumor-Induced Angiogenesis

B. Neustadt, E. Maxwell, L. Armstrong, 2000 .

Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis.

B. Neustadt, E. Maxwell, L. Armstrong, 2000, Advances in experimental medicine and biology.

Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.

B. Neustadt, L. Armstrong, C. Kumar, 2001, Cancer research.

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

W. R. Bishop, L. Nielsen, G. Hajian, 2000, Cancer Chemotherapy and Pharmacology.

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Walter A. Korfmacher, W. R. Bishop, J. Catino, 1998, Cancer research.

Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.

W. R. Bishop, J. Catino, M. Malkowski, 1997, Journal of medicinal chemistry.

Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.

W. R. Bishop, Meilin Liu, L. Nielsen, 1999, Cancer research.

SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models

Lingling Wu, D. Hicklin, E. Lees, 2008 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010, Molecular Cancer Therapeutics.

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010, Molecular Cancer Therapeutics.